Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

King Names COO Markison Acting CEO; President Macione Steps Down

Executive Summary

King Pharmaceuticals Chief Operating Officer Brian Markison has been named acting president and CEO

You may also be interested in...



Mylan Places Big Bet On Antihypertensives: $4 Bil. Deal For King

Mylan's proposed acquisition of King is a big move by the generic company to carve out a leading position in the branded antihypertensive market

King Altace Inventory Levels To Be Stabilized Through Wholesaler Agreements

King Pharmaceuticals is working with wholesalers to implement an inventory reduction program to help stabilize Altace stocking levels, CFO Jim Lattanzi said during a Feb. 19 conference call

King Ups Medicaid Rebate Underpayment Estimate To $65 Mil.; CEO To Depart

King Pharmaceuticals is raising its estimated Medicaid rebate underpayments by $18.9 mil. to $65.4 mil. following the completion of an internal audit, CFO Jim Lattanzi said during a Feb. 19 conference call

Related Content

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel